63,333 results match your criteria Neutropenia


Recombinant human granulocyte- colony stimulating factor in women with unexplained recurrent pregnancy losses: a randomized clinical trial.

Hum Reprod 2019 Feb 18. Epub 2019 Feb 18.

Nora Therapeutics, Inc., 530 Lytton Avenue, 2nd Floor, Palo Alto, CA, USA.

Study Question: Does administration of recombinant human granulocyte colony stimulating factor (rhG-CSF) in the first trimester improve pregnancy outcomes, among women with a history of unexplained recurrent pregnancy loss?

Summary Answer: rhG-CSF administered in the first trimester of pregnancy did not improve outcomes among women with a history of unexplained recurrent pregnancy loss.

What Is Known Already: The only previous randomized controlled study of granulocyte colony stimulating factor in recurrent miscarriage in 68 women with unexplained primary recurrent miscarriage found a statistically significant reduction in miscarriage and improvement in live birth rates. A further four observational studies where G-CSF was used in a recurrent miscarriage population were identified in the literature, two of which confirmed statistically significant increase in clinical pregnancy and live birth rates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/humrep/dey393DOI Listing
February 2019

Is It Appropriate to Place Subcutaneous Chest Ports in Patients with Neutropenia?

Authors:
Evan J Johnson

Radiology 2019 Feb 12:190095. Epub 2019 Feb 12.

From the Department of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2019190095DOI Listing
February 2019

Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.

Cochrane Database Syst Rev 2019 Feb 18;2:CD012873. Epub 2019 Feb 18.

Medical Oncology Department, Concord Repatriation General Hospital, Concord, New South Wales, Australia, 2139.

Background: Anthracyclines and taxanes are chemotherapeutic agents widely used in a sequential regimen in the adjuvant and neoadjuvant treatment of early breast cancer to reduce the risk of cancer recurrence. Standard practice is to administer anthracycline-based chemotherapy followed by a taxane. Anthracyclines tend to be administered first as they were established before taxanes for treatment of early breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD012873.pub2DOI Listing
February 2019
1 Read

Transcatheter arterial chemoembolisation followed by three-dimensional conformal radiotherapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adults.

Cochrane Database Syst Rev 2019 Feb 16;2:CD012244. Epub 2019 Feb 16.

Clinical Research Center, South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, 232 Waihuan Dong Road, Guangzhou, Guangdong, China, 510006.

Background: Hepatocellular carcinoma, also called malignant hepatoma, is a primary malignancy of the liver. Despite regular surveillance conducted in high-risk populations, most people with hepatocellular carcinoma are diagnosed at an advanced stage. Consequently, only a minority of people with the disease are suitable for surgical resection when diagnosed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD012244.pub2DOI Listing
February 2019

Description of an Mutation in a Girl with Severe Congenital Neutropenia: A Paradigm of Targeted Genetic Screening Based on Clinical Findings.

J Pediatr Genet 2019 Mar 15;8(1):33-37. Epub 2018 Sep 15.

Second Department of Pediatrics, School of Medicine, University General Hospital AHEPA, Aristotle University of Thessaloniki, Thessaloniki, Greece.

We describe the case of a 5-year-old girl with severe congenital neutropenia presenting with recurrent skin and respiratory infections. Sequence analysis of and HAX1 genes identified a mutation in heterozygous state in exon 2 of the gene: c.157C > G (p. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0038-1670724DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375722PMC

Clinical characteristics of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.

Cancer Manag Res 2019 23;11:997-1002. Epub 2019 Jan 23.

Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China,

Background: Extranodal natural killer (NK) / T cell lymphoma is a subtype of non-Hodgkin's lymphoma (NHL) that usually has an aggressive clinical course. It is the predominant trigger of lymphoma-associated hemophagocytic syndrome (LAHS), which is highly lethal and with extremely poor prognosis. This study is aiming to characterize the associated clinical features and prognostic factors of the disease. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/clinical-characteristics-of-extran
Publisher Site
http://dx.doi.org/10.2147/CMAR.S183784DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350644PMC
January 2019
4 Reads

Efficacy and safety of nivolumab for metastatic biliary tract cancer.

Onco Targets Ther 2019 25;12:861-867. Epub 2019 Jan 25.

Department of Medical Oncology, Chinese People's Liberation Army General Hospital, Beijing 100853, People's Republic of China,

Objective: PD-1 inhibitors have improved efficacy in many cancers. There are currently no reports of the use of PD-1 inhibitors, such as nivolumab, for metastatic biliary tract cancer (mBTC). This study reviewed the efficacy and safety of nivolumab for mBTC with the aim of exploring ways to improve efficacy and survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S195537DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355165PMC
January 2019

Results of endoscopic nasal surgery in the treatment of invasive fungal sinusitis in children with cancer and immunosuppression.

Acta Otorrinolaringol Esp 2019 Feb 14. Epub 2019 Feb 14.

Departamento de Otorrinolaringología, Centro Clínico de Cabeza y Cuello, Ciudad de Guatemala, Guatemala.

Background And Objective: to describe the results of the treatment of invasive fungal sinusitis with nasal endoscopic surgery in an immunocompromised paediatric oncological population.

Methods: retrospective study of all patients diagnosed with invasive fungal sinusitis operated in the National Paediatric Oncology Unit between 2012 and 2016. Data taken from their medical history included: epidemiological characteristics, oncological diagnosis, haematological data, symptoms, tomographic studies, surgical interventions, results of pathology and cultures, medications received, complications, evolution and survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.otorri.2018.09.001DOI Listing
February 2019

Candida Tropicalis Renal Microabscesses in a Child with Leukemia Confirmed Using Nucleic Acid Amplification and Recovery after Prolonged Antifungal and Corticosteroid Treatment.

Int J Infect Dis 2019 Feb 14. Epub 2019 Feb 14.

Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.

We report the first case of microabscesses detected by polymerase chain reaction (PCR) amplification of nucleic acid from ultrasound-guided aspirated fluid in a three-year old boy with acute lymphoblastic leukemia and febrile neutropenia during induction chemotherapy. Fever persisted despite effective antifungal treatment. The addition of corticosteroid therapy successfully controlled the suspected immune reconstitution inflammatory syndrome (IRIS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijid.2019.02.002DOI Listing
February 2019

The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.

BMC Cancer 2019 Feb 15;19(1):156. Epub 2019 Feb 15.

Department of Urology, Yamagata University, 2-2-2, Iida-nishi, Yamagata, 990-9585, Japan.

Background: We analyzed the efficacy and toxicity of cabazitaxel (CBZ) at high and low initial doses in Japanese patients with docetaxel-resistant castration-resistant prostate cancer (CRPC).

Methods: We retrospectively evaluated 118 patients who received CBZ for docetaxel-resistant CRPC in 10 university hospitals in Japan between 2014 and 2016. The rate of decrease of prostate-specific antigen (PSA), adverse events, progression-free survival (PFS), and overall survival (OS) were compared between patients receiving initially high (≥22. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5342-9DOI Listing
February 2019

Epidemiology and clinical outcomes of invasive mould infections in Indian intensive care units (FISF study).

J Crit Care 2019 Feb 5;51:64-70. Epub 2019 Feb 5.

Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Background And Aim: Due to limited data on invasive mould infections (IMIs) in the intensive care units (ICUs) of developing countries, we ascertain epidemiology and management of IMIs at 11 ICUs across India.

Methods: Consecutive patients with proven or probable/putative IMIs were enrolled during the study period. Subjects were categorized into classical (neutropenia, malignancy, transplant recipients on immunosuppression) and non-classical (chronic obstructive pulmonary disease, diabetes, liver disease and glucocorticoids) risk groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcrc.2019.02.005DOI Listing
February 2019

Successful treatment of chromoblastomycosis using ALA-PDT in a patient with leukopenia.

Photodiagnosis Photodyn Ther 2019 Feb 12. Epub 2019 Feb 12.

Department of Dermatology, Nanfang Hospital, Southern Medical University, 1838 North Avenue, Guangzhou 510515, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pdpdt.2019.02.013DOI Listing
February 2019

Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective.

Pharmacogenomics 2019 Feb 15. Epub 2019 Feb 15.

MRC Centre for Neuropsychiatric Genetics & Genomics, Division of Psychological Medicine & Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, CF24 4HQ, UK.

Clozapine is the only effective antipsychotic for treatment-resistant schizophrenia but remains widely under prescribed, at least in part due to its potential to cause agranulocytosis and neutropenia. In this article, we provide an overview of the current understanding of the genetics of clozapine-associated agranulocytosis and neutropenia. We now know that the genetic etiology of clozapine-associated neutropenia is complex and is likely to involve variants from several genes including HLA-DQB1, HLA-B and SLCO1B3/SLCO1B7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0188DOI Listing
February 2019

Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.

Br J Haematol 2019 Feb 14. Epub 2019 Feb 14.

Celgene Corporation, Summit, NJ, USA.

Chemotherapy plus rituximab has been the mainstay of treatment for follicular lymphoma (FL) for two decades but is associated with immunosuppression and relapse. In phase 2 studies, lenalidomide combined with rituximab (R ) has shown clinical synergy in front-line and relapsed/refractory FL. Here, we show that lenalidomide reactivated dysfunctional T and Natural Killer (NK) cells ex vivo from FL patients by enhancing proliferative capacity and T-helper cell type 1 (Th1) cytokine release. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15797DOI Listing
February 2019
2 Reads

A Phase 2 Study of Induction Chemotherapy Using Docetaxel, Cisplatin, and S-1 for Gastric Cancer with Peritoneal Metastasis (KUGC06).

Ann Surg Oncol 2019 Feb 14. Epub 2019 Feb 14.

Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Background: The authors previously showed the significant efficacy of S-1 plus cisplatin for gastric cancer with limited peritoneal metastasis. They conducted a phase 2 study to evaluate the safety and efficacy of induction chemotherapy using a docetaxel, cisplatin, and S-1 (DCS) triplet regimen to treat gastric cancer with peritoneal metastasis.

Methods: The key eligibility criteria were gastric cancer with peritoneal metastasis or positive peritoneal cytology but no other distant metastases and capability of oral administration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-019-07229-7DOI Listing
February 2019

Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial.

Cardiovasc Intervent Radiol 2019 Feb 14. Epub 2019 Feb 14.

Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.

Purpose: To investigate the safety and toxicity of percutaneous hepatic perfusion with melphalan (M-PHP) with the Delcath Systems' second-generation (GEN 2) filter and compare the outcomes with historical data from studies using the first-generation filter.

Materials And Methods: A prospective, single-arm, single-center phase II study was carried out including 35 patients with unresectable, histologically confirmed liver metastases from ocular melanoma between February 2014 and June 2017. Main exclusion criteria were extrahepatic disease and age > 75 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00270-019-02177-xDOI Listing
February 2019

Safety and efficacy of nimotuzumab with concurrent chemoradiotherapy in unresectable locally advanced squamous cell carcinoma of head and neck: An Indian rural hospital experience.

South Asian J Cancer 2019 Jan-Mar;8(1):52-56

Department of Radiation Oncology, NSCB Medical College and Government Hospital, Jabalpur, Madhya Pradesh, India.

Context: Nimotuzumab is the only anti-epidermal growth factor receptor monoclonal antibody which can be safely added to concurrent chemoradiotherapy (CRT) to improve efficacy in the management of unresectable, locally advanced squamous cell carcinoma of head and neck (LA-SCCHN). However, the evidence available on this is limited.

Aims: We retrospectively investigated efficacy and safety of nimotuzumab when combined with chemoradiation for LA-SCCHN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/sajc.sajc_76_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348788PMC
February 2019

Multiday corticosteroids in cancer chemotherapy delay the diagnosis of and antimicrobial administration for febrile neutropenia: a double-center retrospective study.

J Pharm Health Care Sci 2019 4;5. Epub 2019 Feb 4.

1Department of Clinical Drug Informatics, Faculty of Pharmacy, Institute of Medical, Pharmaceutical & Health Science, Kanazawa University, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641 Japan.

Background: Medical staff should promptly administer antimicrobials to patients with febrile neutropenia (FN) to decrease the mortality related to cancer chemotherapy. Corticosteroids, which are used in cancer chemotherapy, have a fever-suppressive effect. This effect could lead to a blunt fever response and any local signs of infection, especially in patients receiving multiday corticosteroid administration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40780-018-0130-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360780PMC
February 2019

Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study.

Front Neurol 2019 31;10:42. Epub 2019 Jan 31.

The Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center at Houston (UTHealth), McGovern Medical School, Houston, TX, United States.

Clinical studies treating pediatric and adult solid tumors, such as glioblastoma (GBM), with a triple-drug regimen of temozolomide (TMZ), bevacizumab (BEV), and irinotecan (IRI) [TBI] have demonstrated various efficacies, but with no unexpected toxicities. The TBI regimen has never been studied in recurrent GBM (rGBM) patients. In this retrospective study, we investigated the outcomes and side effects of rGBM patients who had received the TBI regimen. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2019.00042DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366009PMC
January 2019

[A Comparative Study on Feasibility of SOX Therapy and SP Therapy with Short Hydration for Gastric Cancer in the Outpatient Setting].

Gan To Kagaku Ryoho 2019 Jan;46(1):187-189

Dept. of Surgery, Osaka Police Hospital.

We conducted a retrospective comparative study on feasibility of S-1/oxaliplatin(SOX)therapy and S-1/cisplatin therapy with short hydration(SP-SH)for gastric cancer in the outpatient setting. The subjects were patients with gastric cancer aged younger than 75 years who underwent SOX or SP-SH therapy at our hospital. There were 22 patients in the SOX group and 30 patients in the SP-SH group. Read More

View Article

Download full-text PDF

Source
January 2019

[A Case of Long-Term Control of Stage Ⅳ Gastric Cancer by Multimodal Therapy].

Gan To Kagaku Ryoho 2019 Jan;46(1):97-99

Dept. of Surgery, Suita Municipal Hospital.

An 82-year-oldwoman was admittedto our hospital because of appetite loss andwas diagnosedwith a Type 3 tumor in the lower gastric body. Pathological examination suggested moderately differentiated adenocarcinoma with negative staining for HER2 by immunohistochemistry. An abdominal CT revealedthickening of the gastric wall andparaaortic lymph node metastases. Read More

View Article

Download full-text PDF

Source
January 2019

[Successful Treatment of Advanced Esophageal Cancer with DCF Chemotherapy and Pegfilgrastim].

Gan To Kagaku Ryoho 2019 Jan;46(1):61-63

Dept. of Gastroenterological Surgery, Graduate School of Medical Science, Kanazawa University.

Docetaxel, cisplatin, and 5-FU(DCF)chemotherapy for esophageal cancer has been reported to be highly effective, but often causes serious adverse events, including severe bone marrow suppression. We report the successful treatment of a 67- year-old man with highly advanced esophageal cancer with invasion of the left bronchus and broad lymph node metastases. He received induction chemotherapy with DCF therapy, and prophylactic administration of pegfilgrastim. Read More

View Article

Download full-text PDF

Source
January 2019

Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response.

PLoS One 2019 14;14(2):e0210891. Epub 2019 Feb 14.

University Hospital Geelong, Geelong, Victoria, Australia.

Background: This study evaluated the feasibility of achieving high response rates in stage II or III breast cancer by tailoring neoadjuvant therapy using clinical and histopathological features and the Oncotype DX Breast Recurrence Score. Genomic determinants of response and resistance were also explored.

Patients And Outcome Measures: Fifty-one patients were enrolled. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210891PLOS
February 2019

Routine surveillance for symptomatic toxicities with real-time clinician reporting in Danish breast cancer patients-Organization and design of the first national, cluster randomized trial using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Breast J 2019 Feb 13. Epub 2019 Feb 13.

Unit of Survivorship, Danish Cancer Society Research Center, Copenhagen, Denmark.

The Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) was developed by the National Cancer Institute to capture patient self-reports of symptomatic toxicities during cancer treatment. The aim of this short communication is to describe the design of a national study, which examine the effect of using patients' electronic PRO-CTCAE reporting with real-time feedback to clinicians on treatment events for breast cancer patients receiving adjuvant chemotherapy. The study's end-points are defined as dose reduction, hospitalization, and febrile neutropenia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/tbj.13204DOI Listing
February 2019

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.

Blood Adv 2019 Feb;3(4):508-518

Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI.

Pracinostat, a potent oral pan-histone deacetylase inhibitor with modest single-agent activity in acute myeloid leukemia (AML), has shown synergistic antitumor activity when combined with azacitidine. This single-group, multicenter phase 2 study assessed the safety and efficacy of pracinostat combined with azacitidine in patients who were at least 65 years old with newly diagnosed AML and who were ineligible for standard induction chemotherapy. Patients received pracinostat 60 mg/d, 3 d/wk, for 3 consecutive weeks, plus azacitidine 75 mg/m daily for 7 days in a 28-day cycle. Read More

View Article

Download full-text PDF

Source
http://www.bloodadvances.org/lookup/doi/10.1182/bloodadvance
Publisher Site
http://dx.doi.org/10.1182/bloodadvances.2018027409DOI Listing
February 2019
2 Reads

Low-Dose Fludarabine and Cyclophosphamide Combined With Standard Dose Rituximab (LD-FCR) Is an Effective and Safe Regimen for Elderly Untreated Patients with Chronic Lymphocytic Leukemia: The Israeli CLL Study Group Experience.

Hematol Oncol 2019 Feb 12. Epub 2019 Feb 12.

Department of Hematology, Hadassah University Hospital and Hebrew University Medical School, Jerusalem, Israel.

Chronic lymphocytic leukemia (CLL) is a disease of elderly patients. The fludarabine, cyclophosphamide and rituximab (FCR) regimen is considered the treatment of choice for young fit patients with CLL, however, this combination is toxic for older patients. At the time this study was first planned and initiated, there was no standard chemo-immunotherapy regimen regarded as standard therapy for the less fit elderly patient with CLL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2580DOI Listing
February 2019

Cardiac Manifestations in Systemic Lupus Erythematosus: Clinical Correlates of Subclinical Echocardiographic Features.

Biomed Res Int 2019 10;2019:2437105. Epub 2019 Jan 10.

Rheumatology Department, Faculty of Medicine, Cairo University, Giza, Egypt.

Objectives: This study aims to correlate subclinical echocardiographic features with the clinical, laboratory, and therapeutic profiles of the patients to characterize risks for systemic lupus erythematosus (SLE) cardiac diseases.

Methods: The study included 59 SLE patients. Demographic data, disease characteristics, and current therapies were recorded, and the anthropometric measurements and routine laboratory tests were performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/2437105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348873PMC
January 2019

Fever of Unknown Origin: Don't Forget Kala-Azar Even in Europe.

Eur J Case Rep Intern Med 2018 22;5(2):000772. Epub 2018 Feb 22.

Haematology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain.

We present the case of a 70-year-old male patient with fever of unknown origin after a long period of convalescence from a previous admission to a chronic care hospital. During the admission, multiple combinations of antibiotic and antifungal treatments were prescribed, but with persistent fever and, eventually, neutropenia (200 lymphocytes, 0 neutrophils). Given the suspicion of infection at bone marrow level, a biopsy was performed as was serology of , both diagnostic determinations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12890/2017_000772DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346938PMC
February 2018

A comparison of cyclophosphamide versus tacrolimus in terms of treatment effect for idiopathic membranous nephropathy: A meta-analysis.

Nefrologia 2019 Feb 9. Epub 2019 Feb 9.

Department of Nephrology, Beijing Chao-Yang Hospital, Beijing, China. Electronic address:

Background And Aims: Idiopathic membranous nephropathy (IMN), which is considered one of the most common causes of nephrotic syndrome in adult patients, is frequently managed with immunosuppressive agents. Both tacrolimus (TAC) and cyclophosphamide (CTX) are recommended as immunosuppressive agents in the management of IMN. However, profound effects and moderate evidence on the two drugs remains poorly defined at this period. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nefro.2018.10.008DOI Listing
February 2019

Association between Periprocedural Neutropenia and Early Infection-related Chest Port Removal.

Radiology 2019 Feb 12:182175. Epub 2019 Feb 12.

From the Vanderbilt University School of Medicine, 2209 Garland Ave, Nashville, TN 37240 (A.W.P., J.M.W.); and Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, Tenn (D.B.B., F.B.).

Background Patients who require long-term central venous access can present for port placement with depressed immune function as a result of their treatment or disease process. At present, there is no consensus regarding whether neutropenia at the time of port placement confers a higher risk for early infection-related port removal. Purpose To compare the incidence of early infection-related chest port removal in adults when placed in neutropenic versus nonneutropenic patient groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2019182175DOI Listing
February 2019

Invasive fungal infection in febrile patients with hematologic malignancies undergoing chemotherapy in Iran.

Endocr Metab Immune Disord Drug Targets 2019 Feb 11. Epub 2019 Feb 11.

Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan. Iran.

Background: Patients with hematological malignancies undergoing cytotoxic chemotherapy are susceptible to develop invasive fungal infections particularly Aspergillus and Candida spp.. Early detection of these infections is required to start immediate antifungal therapy and increase survival of these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1871530319666190211163245DOI Listing
February 2019
1 Read

Functional exercise capacity, strength, balance and motion reaction time in Barth syndrome.

Orphanet J Rare Dis 2019 Feb 11;14(1):37. Epub 2019 Feb 11.

Department of Neurogenetics, Kennedy Krieger Institute, Baltimore, MD, USA.

Background: Barth syndrome (BTHS) is an X-linked disorder caused by defects in TAZ with key clinical features including cardiomyopathy, neutropenia and skeletal myopathy. In order to gain a better understanding of the range of clinical features, identify targets for monitoring, and increase knowledge of natural history of the disease, we conducted muscle strength testing, functional exercise capacity testing, physical activity assessment, balance assessment and motion reaction time testing in 33 affected individuals and 14 controls. We analyzed data points to provide a cross-sectional quantitative spectrum of disease characteristics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13023-019-1006-8DOI Listing
February 2019
1 Read

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.

J Clin Oncol 2019 Feb 11:JCO1800915. Epub 2019 Feb 11.

19 University of Bologna, Bologna, Italy.

Purpose: Indolent non-Hodgkin lymphoma (iNHL) remains largely incurable and often requires multiple lines of treatment after becoming refractory to standard therapies. Duvelisib was approved by the Food and Drug Administration for relapsed or refractory (RR) chronic lymphocytic leukemia or small lymphocytic lymphoma (SLL) and RR follicular lymphoma (FL) after two or more prior systemic therapies. On the basis of the activity of duvelisib, a first-in-class oral dual inhibitor of phosphoinositide 3-kinase-δ,-γ, in RR iNHL in a phase I study, the safety and efficacy of duvelisib monotherapy was evaluated in iNHL refractory to rituximab and either chemotherapy or radioimmunotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.00915DOI Listing
February 2019
1 Read

The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients.

Cancer Med 2019 Feb 10. Epub 2019 Feb 10.

Department of Haematology, Jagiellonian University, Krakow, Poland.

The prognosis of diffuse large B-cell lymphoma (DLBCL) patients depends on lymphoma- and patient-related risk factors and is best estimated by the international prognostic index (IPI). The aim of the study was to determine whether the average relative dose intensity (ARDI) of an anthracycline-containing regimen could predict DLBCL outcome independently from the IPI. We analyzed 223 white Caucasian DLBCL patients who completed at least four cycles of first-line immunochemotherapy with rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R-CHOP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2008DOI Listing
February 2019
1 Read

Piperacillin pharmacokinetics and target attainment in children with cancer and fever: Can we optimize our dosing strategy?

Pediatr Blood Cancer 2019 Feb 10:e27654. Epub 2019 Feb 10.

Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.

Background: Data on piperacillin-tazobactam pharmacokinetics and optimal dosing in children with cancer and fever are limited. Our objective was to investigate piperacillin pharmacokinetics and the probability of target attainment (PTA) with standard intermittent administration (IA), and to simulate PTA in other dosing regimens.

Procedure: This prospective pharmacokinetic study was conducted from April 2016 to January 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.27654DOI Listing
February 2019
1 Read

Organic acid disorders.

Ann Transl Med 2018 Dec;6(24):472

Department of Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan, USA.

Organic acids (OAs) are intermediary products of several amino acid catabolism or degradation via multiple biochemical pathways for energy production. Vitamins or co-factors are often quintessential elements in such degradation pathways and OA metabolism. OAs that result from enzyme defects in these pathways can be identified in body fluids utilizing gas chromatography-mass spectrometry techniques (GC/MS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2018.12.39DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331355PMC
December 2018
2 Reads

Efficacy and Safety of Melphalan, Cyclophosphamide and Dexamethasone (MCD) as a Salvage Treatment for Patients with Relapsed/Refractory Multiple Myeloma.

Chonnam Med J 2019 Jan 25;55(1):25-30. Epub 2019 Jan 25.

Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.

This study investigated the efficacy and safety of melphalan, cyclophosphamide, and dexamethasone (MCD) as a salvage regimen for heavily treated relapsed or refractory multiple myeloma patients. We retrospectively analyzed a total of 27 patients who received the MCD regimen between April 2011 and November 2013. The MCD regimen consisted of oral melphalan 6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4068/cmj.2019.55.1.25DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351330PMC
January 2019
1 Read

Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial.

Eur J Cancer 2019 Feb 7;110:32-41. Epub 2019 Feb 7.

Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Via Roma, 56126 Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Via Roma, 56126 Pisa, Italy. Electronic address:

Background: Neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC) does not achieve effective control of distant metastases. Induction chemotherapy is a promising strategy, and bevacizumab (BV) could improve the results of CRT. 5-Fluorouracil, oxaliplatin and irinotecan (FOLFOXIRI) plus BV is a treatment option in metastatic colorectal cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.01.006DOI Listing
February 2019
1 Read

The Impact of a Multimodal Approach to Vancomycin Discontinuation in Hematopoietic Stem Cell Transplant Recipients (HSCT) with Febrile Neutropenia (FN).

Transpl Infect Dis 2019 Feb 8:e13059. Epub 2019 Feb 8.

Department of Pharmacy Services, Yale-New Haven Hospital, New Haven, CT.

Background: Current guidelines recommend adding vancomycin to empiric treatment of FN in patients who meet specific criteria. After 48 hours, the guidelines recommend discontinuing vancomycin if resistant Gram-positive organisms are not identified. Based on these recommendations, a vancomycin stewardship team defined criteria for discontinuation of vancomycin at 48 hours and increased surveillance of vancomycin usage through a multimodal approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/tid.13059DOI Listing
February 2019
1 Read

Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.

Clin Breast Cancer 2018 Dec 14. Epub 2018 Dec 14.

Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address:

Introduction: Angiogenesis and epidermal growth factor receptor signaling are potential therapeutic targets in triple negative breast cancer (TNBC). We hypothesized that targeting these critical pathways would prolong progression-free survival with first-line therapy for metastatic TNBC.

Patients And Methods: We conducted a phase II trial of nab-paclitaxel and bevacizumab, followed by maintenance therapy with bevacizumab and erlotinib, for patients with metastatic TNBC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.008DOI Listing
December 2018
2 Reads

Primary pulmonary lymphoma in children.

Orphanet J Rare Dis 2019 Feb 8;14(1):35. Epub 2019 Feb 8.

Department of Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, Nanlishi Road 56, Xicheng District, Beijing, China.

Background: Primary pulmonary lymphoma (PPL) is a rare disease, especially in children. We analyse the clinical features of PPL in 4 children to strengthen a understanding of it.

Results: We reported a case series of 4 pediatric patients with PPLs including three diffuse large B-cell lymphomas and one natural killer-T cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13023-019-1009-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368794PMC
February 2019
1 Read

A Retrospective Analysis of the Effects of Chemotherapy-Induced Neutropenia on Overall Survival in Patients With Unresectable or Metastatic Urothelial Carcinoma to Gemcitabine Plus Cisplatin Combination Chemotherapy.

Ann Pharmacother 2019 Feb 8:1060028019830785. Epub 2019 Feb 8.

1 SEIREI Hamamatsu General Hospital, Naka-ku, Japan.

Background: Chemotherapy-induced neutropenia (CIN) is an important dose-limiting toxicity of chemotherapy. However, evidence suggests that the occurrence of CIN may be predictive of treatment outcome. Indeed, studies have revealed that the onset of CIN is associated with a good chemotherapeutic response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019830785DOI Listing
February 2019
1 Read

Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.

Breast J 2019 Feb 8. Epub 2019 Feb 8.

Medical Oncology Department, Hospital 12 De Octubre, Madrid, Spain.

Eribulin is active and safe in heavily pre-treated metastatic breast cancer patients. Few safety data have been published in third line. We aimed to report the specific safety profile on third line beyond taxanes and anthracyclines in advanced breast cancer (ABC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/tbj.13199DOI Listing
February 2019
1 Read

Fifteen-minute consultation: Recognising primary immune deficiencies in children.

Arch Dis Child Educ Pract Ed 2019 Feb 7. Epub 2019 Feb 7.

Department of Paediatrics, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.

Children with primary immunodeficiency syndromes present with broad variation of clinical features and the consequences are often severe if not promptly recognised. Here, support is provided for the general paediatrician to recognise primary immunodeficiencies among the many children they meet in their clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/archdischild-2018-315484DOI Listing
February 2019
1 Read

Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer.

Medicine (Baltimore) 2019 Feb;98(6):e14254

Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai.

Custirsen is the second-generation antisense oligonucleotide (ASO), which can reduce cellular levels of clusterin to increase the cytotoxic effect of chemotherapeutic drugs. Our study assessed the efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer (mCRPC).We conducted a comprehensive search to identify all the randomized controlled trials (RCTs) of custirsen for the treatment of mCRPC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014254DOI Listing
February 2019
1 Read

Acanthocytosis and brain damage in area postrema and choroid plexus: Description of novel signs of Loxosceles apachea envenomation in rats.

PLoS One 2019 7;14(2):e0211689. Epub 2019 Feb 7.

Laboratorio de Biología Molecular y Bioquímica, Departamento de Ciencias Químico Biológicas, Instituto de Ciencias Biomédicas, Universidad Autónoma de Ciudad Juárez, Ciudad Juárez, Chihuahua, México.

Loxocelism is a neglected medical problem that depends on its severity, can cause a cutaneous or viscero-cutaneous syndrome. This syndrome is characterized by hemostatic effects and necrosis, and the severity of the loxoscelism depends on the amount of venom injected, the zone of inoculation, and the species. In the Chihuahuan desert, the most abundant species is L. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211689PLOS
February 2019
1 Read

Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.

BMC Cancer 2019 Feb 6;19(1):122. Epub 2019 Feb 6.

Gedeon Richter Plc, Budapest, Hungary; Gyömröi út 19-21, Budapest, 1103, Hungary.

Background: Treatment with recombinant human granulocyte-colony stimulating factor (G-CSF) is accepted standard for prevention of chemotherapy-induced neutropenia. RGB-02 (Gedeon Richter) is a proposed biosimilar to pegylated G-CSF (Neulasta®, Amgen) with sustained release properties. This is a randomized, comparative, double-blind, multicenter study to evaluate efficacy and safety of RGB-02 in breast cancer patients receiving cytotoxic regimen. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5329-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364429PMC
February 2019
1 Read

A Case of Aplastic Anemia Associated With Long-Term Metronidazole Use.

J Pharm Pract 2019 Feb 6:897190019825584. Epub 2019 Feb 6.

4 Division of Blood and Marrow Transplantation, Department of Medicine, UC San Diego Health, La Jolla, CA, USA.

Metronidazole is a nitroimidazole antibacterial agent that is highly effective for the treatment of protozoal and anaerobic infections. Metronidazole is known to cause hematologic adverse effects, including a reversible mild neutropenia; in rare circumstances, thrombocytopenia has been associated with metronidazole treatment. We present a case of aplastic anemia related to the extended use of metronidazole. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0897190019825584DOI Listing
February 2019
1 Read